Q1 report 2025

en sv de

Clinical evidence
Products
Support
About us
Investors

Q1 report 2025

Apr 22, 2025 08:30

The Q1 report for 2025 will be published April 22, 2025, 08:30 AM CEST.

Headquarters

Senzime AB
Uppsala, Sweden

[email protected]
+46 18 515 640

US office
Senzime Inc.
St. Louis, MO

[email protected]
+1-800-213-1324

Quick links

Contact
Investors
News

Our products

TetraGraph
ExSpiron
Instructions for use

en sv de

Clinical evidence
Products
Support
About us
Investors

Clinical evidence

Evidence on neuromuscular monitoring

Sugammadex and monitoring

Robotic-assisted surgery

Pediatrics

Backed by evidence and guidelines

TetraGraph is the clinically proven standard in neuromuscular monitoring.

Explore evidence

Products

Next-generation TetraGraph

TetraGraph connectivity

TetraGraph

ExSpiron

What we do

Patient monitoring devices for monitoring neuromuscular blockade and respiratory function during and after surgery.

Explore products

Support

Blogs, webinars, videos

Events

Clinical support

Senzime Academy

Next-Generation TetraGraph Support

Elevate your practice

We're here to support you in elevating your practice. Start today by reading a blog, watching a video or a webinar.

Get started

About us

Strategy and business model

Innovation and partnerships

Management team

Sustainability

Careers

News & media

Who we are

A leading medical device company with a mission to safeguard every patient's journey, from anesthesia to recovery.

Explore Senzime

Press releases

Subscription service

Media toolkit

Investors

Investment case

Our strategy & business model

Reports & presentations

Press releases

Prospectus

Calendar

The share

Corporate Governance

A leading global medical device company

Revolutionizing perioperative care for 100 million patients globally.

Why invest in Senzime

Articles of Association